Publication Date

Spring 2016


School of Health Sciences


Biology: Biomedical Sciences


Human Rotavirus, HRV, Rotavirus, Immunoglobulin Y, IgY, Anti-HRV IgY, Passive Oral Immunotherapy, Adjunct Therapy, Rotavirus Vaccines, Child Mortality, Millennium Development Goals, Sustainable Development Goals


Digestive System Diseases | Gastroenterology | Infectious Disease | Medical Immunology | Medicine and Health Sciences | Pediatrics | Preventive Medicine | Public Health | Virus Diseases


Rotavirus gastroenteritis is a leading cause of childhood mortality, killing ~1400 children younger than five daily, primarily through severe diarrheal dehydration. Eighty-five percent of this mortality occurs in developing countries where rotavirus vaccines are not widely implemented and are only partially effective. In those countries, it has proven difficult to implement the recommended supportive therapies like oral rehydration therapy (ORT) on a wide scale due to lack of both medical infrastructure and private economic investment combined with cultural bias against ORT. IgY targeting human rotavirus (anti-HRV IgY) shows potential as a passive immunotherapy that reduces rotavirus-associated morbidity and mortality, augments vaccine and ORT implementation measures, and, with international and local investment, overcomes the current barriers to rotavirus treatment and prevention.

Tate FIGURE LICENSE-RightsLink Printable License.pdf (228 kB)
Fig. 1. copyright permission

NatureReviewsLicense-Rotavirus Particle.pdf (141 kB)
Fig. 2. copyright permission

Figure Permission Kovacs Nolan.JPG (58 kB)
Fig. 3. & Fig. 4. copyright permission

RightsLink Printable License--Seq Separation.pdf (134 kB)
Fig. 5. copyright permission